Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

Cell and gene therapy; Meeting on the Mesa; Commercialization; Clinical trials; Advanced therapies; Industry partnerships; Regulatory challenges; Phoenix Arizona; mRNA; Gene editing; Alternative payment models

CRISPR Therapeutics Partners with Sirius for siRNA Therapies, Expanding Beyond Gene Editing

CRISPR Therapeutics; Sirius Therapeutics; siRNA; gene editing; SRSD107; cardiovascular diseases; thrombotic disease; biotech partnerships; Factor XI; anticoagulant therapies

Federal Appeals Court Revives CRISPR Patent Dispute Between Broad Institute and University of California

CRISPR; patent dispute; Broad Institute; University of California; Federal Circuit; PTAB; gene editing; intellectual property; eukaryotic cells

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes

Biotech Breakthroughs 2025: Emerging Trends and Technologies Shaping the Industry’s Future

CRISPR therapeutics, solid-state batteries, precision medicine, AI in drug discovery, gene editing, cancer vaccines, personalized therapies, biotech investment, platform technologies, clinical trial innovation